Cancer drug olaparib linked to folate deficiency in small study
NCT ID NCT04024254
First seen Nov 21, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study checked if the drug olaparib, used for advanced ovarian or breast cancer, leads to low folic acid levels in the blood. Ten postmenopausal women were followed to see how many developed folate deficiency and when. The goal was to understand a possible side effect of this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.